|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
60,492,000 |
Market
Cap: |
N/A |
Last
Volume: |
5,682,564 |
Avg
Vol: |
2,660,715 |
52
Week Range: |
$31.96 - $31.96 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Willow Acquisition Sub Corp |
10% Owner |
|
2014-01-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
100 |
|
- |
|
Wierenga Wendall D |
EVP, R&D |
|
2014-01-02 |
4 |
D |
$32.00 |
$10,048 |
D/D |
(314) |
0 |
|
- |
|
Wierenga Wendall D |
EVP, R&D |
|
2014-01-02 |
4 |
D |
$32.00 |
$150,848 |
D/D |
(4,714) |
0 |
|
- |
|
Totoritis Mark |
SVP, Clinical Research |
|
2014-01-02 |
4 |
D |
$32.00 |
$1,766,112 |
D/D |
(55,191) |
0 |
|
- |
|
Totoritis Mark |
SVP, Clinical Research |
|
2014-01-02 |
4 |
D |
$32.00 |
$4,009,312 |
D/D |
(125,291) |
55,191 |
|
- |
|
Totoritis Mark |
SVP, Clinical Research |
|
2014-01-02 |
4 |
D |
$32.00 |
$399,968 |
D/D |
(12,499) |
180,482 |
|
- |
|
Totoritis Mark |
SVP, Clinical Research |
|
2014-01-02 |
4 |
A |
$3.15 |
$399,995 |
D/D |
124,443 |
192,981 |
|
- |
|
Proehl Gerald T |
President & CEO |
|
2014-01-02 |
4 |
D |
$32.00 |
$9,537,056 |
I/I |
(298,033) |
0 |
|
- |
|
Proehl Gerald T |
President & CEO |
|
2014-01-02 |
4 |
D |
$32.00 |
$999,968 |
I/I |
(31,249) |
298,033 |
|
- |
|
Proehl Gerald T |
President & CEO |
|
2014-01-02 |
4 |
D |
$32.00 |
$977,216 |
D/D |
(30,538) |
0 |
|
- |
|
Proehl Gerald T |
President & CEO |
|
2014-01-02 |
4 |
D |
$32.00 |
$7,466,912 |
D/D |
(233,341) |
30,538 |
|
- |
|
Proehl Gerald T |
President & CEO |
|
2014-01-02 |
4 |
A |
$1.18 |
$999,996 |
D/D |
233,341 |
263,879 |
|
- |
|
Step Michael D |
SVP, Corporate Development |
|
2014-01-02 |
4 |
D |
$32.00 |
$23,296 |
D/D |
(728) |
0 |
|
- |
|
Step Michael D |
SVP, Corporate Development |
|
2014-01-02 |
4 |
D |
$32.00 |
$4,983,520 |
D/D |
(155,735) |
728 |
|
- |
|
Step Michael D |
SVP, Corporate Development |
|
2014-01-02 |
4 |
D |
$32.00 |
$47,904 |
D/D |
(1,497) |
156,463 |
|
- |
|
Step Michael D |
SVP, Corporate Development |
|
2014-01-02 |
4 |
A |
$1.18 |
$812,759 |
D/D |
155,735 |
157,960 |
|
- |
|
Hall Warren E |
Sr. VP, Mfg. & Prod. Dev. |
|
2014-01-02 |
4 |
D |
$32.00 |
$6,521,312 |
D/D |
(203,791) |
0 |
|
- |
|
Hall Warren E |
Sr. VP, Mfg. & Prod. Dev. |
|
2014-01-02 |
4 |
D |
$32.00 |
$244,160 |
D/D |
(7,630) |
203,791 |
|
- |
|
Hall Warren E |
Sr. VP, Mfg. & Prod. Dev. |
|
2014-01-02 |
4 |
A |
$1.18 |
$977,473 |
D/D |
203,167 |
211,421 |
|
- |
|
De Meules Julie A |
Sr. VP, Human Resources |
|
2014-01-02 |
4 |
D |
$32.00 |
$14,176 |
D/D |
(443) |
0 |
|
- |
|
De Meules Julie A |
Sr. VP, Human Resources |
|
2014-01-02 |
4 |
D |
$32.00 |
$4,790,720 |
D/D |
(149,710) |
443 |
|
- |
|
De Meules Julie A |
Sr. VP, Human Resources |
|
2014-01-02 |
4 |
A |
$2.36 |
$883,132 |
D/D |
149,710 |
150,153 |
|
- |
|
Denby William C |
Sr. VP, Commercial Operations |
|
2014-01-02 |
4 |
D |
$32.00 |
$975,104 |
D/D |
(30,472) |
0 |
|
- |
|
Denby William C |
Sr. VP, Commercial Operations |
|
2014-01-02 |
4 |
D |
$32.00 |
$4,640,480 |
D/D |
(145,015) |
30,472 |
|
- |
|
Denby William C |
Sr. VP, Commercial Operations |
|
2014-01-02 |
4 |
D |
$32.00 |
$854,240 |
D/D |
(26,695) |
175,487 |
|
- |
|
417 Records found
|
|
Page 1 of 17 |
|
|